JP2021524244A5 - - Google Patents
Info
- Publication number
- JP2021524244A5 JP2021524244A5 JP2020564908A JP2020564908A JP2021524244A5 JP 2021524244 A5 JP2021524244 A5 JP 2021524244A5 JP 2020564908 A JP2020564908 A JP 2020564908A JP 2020564908 A JP2020564908 A JP 2020564908A JP 2021524244 A5 JP2021524244 A5 JP 2021524244A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- variable region
- polypeptide sequence
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862676123P | 2018-05-24 | 2018-05-24 | |
| US62/676,123 | 2018-05-24 | ||
| US201962825846P | 2019-03-29 | 2019-03-29 | |
| US62/825,846 | 2019-03-29 | ||
| PCT/IB2019/054182 WO2019224711A2 (en) | 2018-05-24 | 2019-05-21 | Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021524244A JP2021524244A (ja) | 2021-09-13 |
| JP2021524244A5 true JP2021524244A5 (https=) | 2022-05-25 |
| JP7530298B2 JP7530298B2 (ja) | 2024-08-07 |
Family
ID=67211770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564908A Active JP7530298B2 (ja) | 2018-05-24 | 2019-05-21 | 抗ｃｄ３３抗体、抗ｃｄ３３／抗ｃｄ３二重特異性抗体、及びその使用 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11466082B2 (https=) |
| EP (1) | EP3802606B1 (https=) |
| JP (1) | JP7530298B2 (https=) |
| KR (1) | KR102890653B1 (https=) |
| CN (1) | CN112189022B (https=) |
| AU (1) | AU2019274229B2 (https=) |
| BR (1) | BR112020023357A2 (https=) |
| CL (1) | CL2020003028A1 (https=) |
| CO (1) | CO2020014575A2 (https=) |
| CR (1) | CR20200567A (https=) |
| EC (1) | ECSP20075198A (https=) |
| ES (1) | ES2998890T3 (https=) |
| IL (1) | IL278844A (https=) |
| JO (1) | JOP20190116A1 (https=) |
| MA (1) | MA52771A (https=) |
| MX (1) | MX2020012588A (https=) |
| NI (1) | NI202000088A (https=) |
| PE (1) | PE20210180A1 (https=) |
| PH (1) | PH12020552010A1 (https=) |
| SG (1) | SG11202011210TA (https=) |
| TW (1) | TW202033551A (https=) |
| UY (1) | UY38242A (https=) |
| WO (1) | WO2019224711A2 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10738118B2 (en) | 2015-05-29 | 2020-08-11 | Amphivena Therapeutics, Inc. | Methods of using bispecific CD33 and CD3 binding proteins |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| CA3101271A1 (en) | 2018-05-24 | 2019-11-28 | Janssen Biotech, Inc. | Anti-cd3 antibodies and uses thereof |
| CR20210155A (es) | 2018-08-31 | 2021-05-10 | Alector Llc | Anticuerpos anti-cd33 y métodos para usarlos |
| DE102018127845A1 (de) | 2018-11-07 | 2020-05-07 | Grimme Landmaschinenfabrik Gmbh & Co. Kg | Verfahren zur Regelung des Betriebs einer Maschine zum Ernten von Hackfrüchten |
| CA3131019A1 (en) | 2019-02-22 | 2020-08-27 | Memorial Sloan Kettering Cancer Center | Cd33 antibodies and methods of using the same to treat cancer |
| CN113766930B (zh) | 2019-02-26 | 2025-07-22 | 特韦斯特生物科学公司 | Glp1受体的变异核酸文库 |
| BR112022011235A2 (pt) | 2019-12-09 | 2022-12-13 | Twist Bioscience Corp | Bibliotecas de variantes de ácido nucleico para receptores de adenosina |
| AU2021225870A1 (en) * | 2020-02-27 | 2022-10-20 | Janssen Biotech, Inc. | Materials and methods for modulating an immune response |
| US20210284731A1 (en) * | 2020-03-13 | 2021-09-16 | Janssen Biotech, Inc. | Methods and materials for modulating an immune response |
| IL296358A (en) * | 2020-03-13 | 2022-11-01 | Janssen Biotech Inc | Materials and methods for modulating delta chain mediated immunity |
| JP2023517660A (ja) * | 2020-03-13 | 2023-04-26 | ヤンセン バイオテツク，インコーポレーテツド | シグレック３／ｃｄ３３に結合させるための材料及び方法 |
| JP2023520410A (ja) * | 2020-03-31 | 2023-05-17 | フレッド ハッチンソン キャンサー センター | Ｃｄ３３を標的にするキメラ抗原受容体 |
| CN115348973A (zh) | 2020-03-31 | 2022-11-15 | 弗莱德哈钦森癌症中心 | 靶向cd33的嵌合抗原受体 |
| CN115297932A (zh) * | 2020-03-31 | 2022-11-04 | 弗莱德哈钦森癌症中心 | 抗cd33抗体和其用途 |
| CN113461817B (zh) * | 2020-03-31 | 2025-04-18 | 苏州泽璟生物制药股份有限公司 | 一种抗人cd47抗体及其抗原结合片段、制备方法和应用 |
| WO2021231237A2 (en) * | 2020-05-11 | 2021-11-18 | Augmenta Bioworks, Inc. | Antibodies for sars-cov-2 and uses thereof |
| CN116249714A (zh) | 2020-05-27 | 2023-06-09 | 詹森生物科技公司 | 包含cd3抗原结合结构域的蛋白质及其用途 |
| MX2023003041A (es) | 2020-09-16 | 2023-05-09 | Amgen Inc | Métodos para administrar dosis terapéuticas de moléculas de acoplamiento a células t biespecíficas para el tratamiento de cáncer. |
| KR20230147617A (ko) | 2021-01-21 | 2023-10-23 | 트위스트 바이오사이언스 코포레이션 | 아데노신 수용체에 관한 방법 및 조성물 |
| JP2024507180A (ja) | 2021-02-16 | 2024-02-16 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｂｃｍａ、ｇｐｒｃ５ｄ、及びｃｄ３を標的とする三重特異的抗体 |
| JP7714675B2 (ja) | 2021-03-24 | 2025-07-29 | ヤンセン バイオテツク，インコーポレーテツド | ＣＤ７９ｂ、ＣＤ２０、及びＣＤ３を標的とする三重特異性抗体 |
| CN120249215A (zh) * | 2021-04-27 | 2025-07-04 | 上海驯鹿生物技术有限公司 | 一种基因编辑的造血干细胞及其与car-t细胞的联合应用 |
| US20250082754A1 (en) * | 2021-07-30 | 2025-03-13 | Nanjing Legend Biotech Co., Ltd. | Anti-cd33 antibodies and uses thereof |
| AU2022340645A1 (en) * | 2021-09-02 | 2024-02-29 | Memorial Hospital For Cancer And Allied Diseases | Anti-cd33 antibodies and uses thereof |
| CA3229822A1 (en) * | 2021-09-13 | 2023-03-16 | Patrick John DOONAN | Cd33 x v?2 multispecific antibodies for the treatment of cancer |
| WO2023081898A1 (en) * | 2021-11-08 | 2023-05-11 | Alector Llc | Soluble cd33 as a biomarker for anti-cd33 efficacy |
| JP2026502768A (ja) * | 2022-10-25 | 2026-01-27 | アブレクシス， エルエルシー | 抗ｃｄ３抗体 |
| WO2025120583A2 (en) * | 2023-12-08 | 2025-06-12 | Janssen Biotech, Inc. | CD33 ANTIBODIES, CD33/Vδ2 MULTISPECIFIC ANTIBODIES AND USES THEREOF |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| WO2025174974A1 (en) * | 2024-02-14 | 2025-08-21 | Bristol-Myers Squibb Company | Anti-cd33 antibodies and uses thereof |
| CN118221826B (zh) * | 2024-04-25 | 2024-11-15 | 北京绿竹生物技术股份有限公司 | 一种结合人cd33和cd3的双特异性抗体 |
| WO2026006492A2 (en) | 2024-06-25 | 2026-01-02 | Ypsilon Therapeutics, Inc. | Anti-prame/hla-a2 antibodies and uses thereof |
| WO2026006495A1 (en) | 2024-06-25 | 2026-01-02 | Alloy Therapeutics, Inc. | Anti-wt1/hla-a2 antibody and uses thereof |
| CN119804863B (zh) * | 2025-03-13 | 2025-06-17 | 北京华诺泰生物医药科技有限公司 | 检测人偏肺病毒抗原的酶联免疫试剂盒及定量检测方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US20020142000A1 (en) | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
| ZA200503075B (en) | 2002-11-07 | 2006-09-27 | Immunogen Inc | Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same |
| WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| EP1940881B1 (en) | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
| JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー／エス | 二重特異性抗体の生産 |
| RU2769948C2 (ru) | 2007-04-03 | 2022-04-11 | Эмджен Рисерч (Мьюник) Гмбх | CD3-Эпсилон-связывающий домен с межвидовой специфичностью |
| MX2009010611A (es) | 2007-04-03 | 2010-03-26 | Micromet Ag | Enlazadores biespecificos, especificos para especies. |
| RS53008B2 (sr) | 2007-04-03 | 2022-12-30 | Amgen Res Munich Gmbh | Interspecijski specifičan cd3-epsilon vezujući domen |
| EP2352765B1 (en) | 2008-10-01 | 2018-01-03 | Amgen Research (Munich) GmbH | Cross-species-specific single domain bispecific single chain antibody |
| DK2352763T4 (da) | 2008-10-01 | 2022-10-17 | Amgen Res Munich Gmbh | Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener |
| US20110293619A1 (en) | 2008-10-01 | 2011-12-01 | Micromet Ag | CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY |
| WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| HRP20241208T1 (hr) | 2010-04-20 | 2024-11-22 | Genmab A/S | Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju |
| UA112062C2 (uk) | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
| ES2758994T3 (es) | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
| BR112014010580B1 (pt) | 2011-11-04 | 2021-01-12 | Zymeworks, Inc. | constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado |
| US20130309223A1 (en) * | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
| PT2931030T (pt) | 2012-12-14 | 2020-08-03 | Open Monoclonal Tech Inc | Polinucleótidos que codificam anticorpos de roedores com idiótipos humanos e animais que os compreendem |
| AR097648A1 (es) | 2013-09-13 | 2016-04-06 | Amgen Inc | Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide |
| SG11201604784XA (en) | 2013-12-13 | 2016-07-28 | Genentech Inc | Anti-cd33 antibodies and immunoconjugates |
| US9212225B1 (en) | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
| MA40609B1 (fr) * | 2014-09-05 | 2020-05-29 | Janssen Pharmaceutica Nv | Agents de liaison cd123 et leurs utilisations |
| HK1252675A1 (zh) | 2015-06-12 | 2019-05-31 | Alector Llc | 抗cd33抗体及其使用方法 |
| AU2016276981B2 (en) * | 2015-06-12 | 2022-10-06 | Alector Llc | Anti-CD33 antibodies and methods of use thereof |
| BR112019023789A2 (pt) | 2017-08-03 | 2020-07-28 | Alector Llc | anticorpos anti-cd33 e métodos de uso dos mesmos |
| BR112020016944A2 (pt) | 2018-02-20 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Domínios variáveis de anticorpo que alvejam cd33 e uso dos mesmos |
| CA3101271A1 (en) * | 2018-05-24 | 2019-11-28 | Janssen Biotech, Inc. | Anti-cd3 antibodies and uses thereof |
-
2018
- 2018-05-24 JO JOP/2019/0116A patent/JOP20190116A1/ar unknown
-
2019
- 2019-05-21 JP JP2020564908A patent/JP7530298B2/ja active Active
- 2019-05-21 MA MA052771A patent/MA52771A/fr unknown
- 2019-05-21 BR BR112020023357-9A patent/BR112020023357A2/pt unknown
- 2019-05-21 CN CN201980034952.6A patent/CN112189022B/zh active Active
- 2019-05-21 KR KR1020207036865A patent/KR102890653B1/ko active Active
- 2019-05-21 WO PCT/IB2019/054182 patent/WO2019224711A2/en not_active Ceased
- 2019-05-21 AU AU2019274229A patent/AU2019274229B2/en active Active
- 2019-05-21 ES ES19737216T patent/ES2998890T3/es active Active
- 2019-05-21 EP EP19737216.2A patent/EP3802606B1/en active Active
- 2019-05-21 CR CR20200567A patent/CR20200567A/es unknown
- 2019-05-21 PE PE2020001885A patent/PE20210180A1/es unknown
- 2019-05-21 US US16/418,420 patent/US11466082B2/en active Active
- 2019-05-21 MX MX2020012588A patent/MX2020012588A/es unknown
- 2019-05-21 SG SG11202011210TA patent/SG11202011210TA/en unknown
- 2019-05-23 TW TW108117806A patent/TW202033551A/zh unknown
- 2019-05-24 UY UY0001038242A patent/UY38242A/es unknown
-
2020
- 2020-11-19 IL IL278844A patent/IL278844A/en unknown
- 2020-11-20 CL CL2020003028A patent/CL2020003028A1/es unknown
- 2020-11-23 NI NI202000088A patent/NI202000088A/es unknown
- 2020-11-23 PH PH12020552010A patent/PH12020552010A1/en unknown
- 2020-11-23 EC ECSENADI202075198A patent/ECSP20075198A/es unknown
- 2020-11-24 CO CONC2020/0014575A patent/CO2020014575A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021524244A5 (https=) | ||
| JP2021514664A5 (https=) | ||
| IL276830B1 (en) | Anti-claudin 18.2 antibodies and their uses | |
| AU2016306090B2 (en) | 5-bromo-2,6-di-(1H-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer | |
| JP2018534933A5 (https=) | ||
| CN114502591B (zh) | 靶向bcma的抗体、双特异性抗体及其用途 | |
| JP2021524256A5 (https=) | ||
| JP2022510964A5 (https=) | ||
| JP2021526022A5 (https=) | ||
| JP2016505556A5 (https=) | ||
| JP2019531764A5 (https=) | ||
| JP2017529838A5 (https=) | ||
| RU2016137110A (ru) | Антитела к компоненту комплемента с5 | |
| JP2017534256A5 (https=) | ||
| RU2010107175A (ru) | Антитела человека к cd20 человека и способ их использования | |
| JP2021510736A5 (https=) | ||
| JP2021528047A5 (https=) | ||
| JP2022533538A5 (https=) | ||
| RU2019139093A (ru) | Фармацевтическая композиция на основе антитела к pd-l1 и ее применение | |
| JP2021520825A5 (https=) | ||
| JP2020522280A5 (https=) | ||
| JP2020522281A5 (https=) | ||
| JP2024540148A5 (https=) | ||
| JP2021523100A5 (https=) | ||
| JP2021512652A5 (https=) |